<DOC>
	<DOC>NCT02921646</DOC>
	<brief_summary>The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.</brief_summary>
	<brief_title>Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Pancreatic metastatic cancer Patient older than 18 years Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with NabPaclitaxel. At least one measurable target lesion Patient signed consent for EnergiePancreas study participation Other concomitant cancer Major general status alteration ( Performance status = 3 or 4 at inclusion) Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (&lt; 1 month), ongoing Healing, hyperthyroidism. Smoker Patient deprived of his liberty, under guardianship, curator. Pregnant patient or breastfeeding Claustrophobic patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>energetic expenditure</keyword>
</DOC>